Channel BannerChannel Banner
ynyYvM7rzQ0ynyYvM7rzQ0

Two new vaccines work

238,349
Socialcounts.OrgEnter Fullscreen (f)
7,087
likes
2,993
comments
daily view 0
monthly view 0

Share

Live Analytics

Comments 0

Two new vaccines work Analytics Table

Income Estimates for Two new vaccines work

Based on this YouTube video's total view count of 238K views and industry-standard rates, the estimated total earning is $167 - $477 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

About Two new vaccines work

Explore Two new vaccines work with 238,349 views, 7,087 likes, and 2,993 comments. Experience the impact of this video content that has captured audience attention.

Novavax https://www.novavax.com/covid-19-coronavirus-vaccine-candidate-updates https://www.gov.uk/government/news/novavax-publishes-positive-efficacy-data-for-its-covid-19-vaccine US company, US and UK science Operation Warp Speed Engineered viral protein, with a plant-based ingredient Normal fridge UK, N = 15,000 Over the age of 65, n = 4,000 NVX-CoV2373 Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial First to Demonstrate Clinical Efficacy Against UK and South Africa Variants 51% of phase 3 participants had new UK variant Efficacy against old strain = 95.6% Efficacy against new variant = 85.6% Based on 62 cases 56 cases in the placebo group 6 cases in the vaccine group Of the 62 cases, 61 were mild or moderate, and 1 was severe (in placebo group). Safety Interim analysis Severe, serious, and medically attended adverse events occurred at low levels Balanced between vaccine and placebo groups Clive Dix, Chair, UK Vaccine Taskforce These are spectacular results The efficacy shown against the emerging variants is also extremely encouraging UK timelines UK, 60 million doses, second half of 2021 Made in Teesside, north east England FUJIFILM Diosynth Biotechnologies’s facilities in Billingham Company is planning to submit its data to the regulators Over to Medicines and Healthcare products Regulatory Agency (MHRA) Joint Committee on Vaccination and Immunisation (JCVI) South Africa Novavax Results N = 4,400 Phase 2b clinical trial Approximately 92.6% of cases attributed to South Africa variant Triple mutant variant, 3 critical mutations in the receptor binding domain (RBD) Multiple mutations outside the RBD HIV Negative participants 94% of the study population was HIV-negative 60% efficacy for disease prevention One severe case in the placebo group All other cases mild or moderate HIV-positive participants (19% of adults) 49.4% efficacy Also about South Africa Prior infection with COVID-19 may not completely protect against subsequent infection by the South Africa escape variant Vaccination with NVX-CoV2373 provided significant protection Novavax, working on a vaccine specifically targeted to the variant Novavax, US and Mexico phase 3 trial Significant progress on PREVENT-19 Clinical Trial in US and Mexico PREVENT-19 has randomized over 16,000 participants Complete targeted enrolment of 30,000 patients in the first half of February Janssen, J and J https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial Adenovirus vector Fridge temperatures Phase 3, ENSEMBLE, 29th January N = 43,783 468 symptomatic cases Efficacy in preventing disease 66% effective overall in preventing disease United States, 72% efficacy Latin America, 66% South Africa, 57% 28 days post-vaccination Onset of protection was observed as early as day 14 Efficacy in preventing severe disease at 28 days Globally, 85 % Demonstrated complete protection against COVID-related hospitalization and death, 28 days post-vaccination. In all adults 18 years and older Efficacy against severe disease increased over time, with no cases in vaccinated participants reported after day 49 Protection Generally consistent across race, age groups, including adults over 60 years of age (N= 13,610) Including South Africa where nearly all cases B.1.351 lineage Safety Data Independent group of experts Did not report any significant safety concerns Vaccine candidate was generally well-tolerated. Fever rates were 9% Overall serious adverse events (SAEs) reported were higher in participants who received placebo as compared to the active vaccine candidate No anaphylaxis was observed Rollout About £7 per dose (not for profit) UK, ordered 30 million doses 8 plants in 7 countries Over to, Medicines and Healthcare products Regulatory Agency (MHRA) Joint Committee on Vaccination and Immunisation (JCVI)

About YouTube Real-Time View Count

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.

Embed Widget

Parameters:

  • fullscreen=true - Fullscreen counter
  • graph=true - Live graph chart
  • counter=0/1/2 - Select counter (0=likes, 1=views, 2=comments)
URL

Click to copy the embed URL to your clipboard